#United States #New York #Class Action #Securities Fraud #Actinium Pharmaceutical

Class Action Lawsuit Against Actinium Pharmaceuticals, Inc.

In a significant development for investors, Pomerantz LLP has issued an alert regarding a class action lawsuit filed against Actinium Pharmaceuticals, Inc. (NYSE: ATNM), signaling potential securities fraud or unlawful business practices orchestrated by the company's directors. This notice is particularly vital for those who may have incurred losses due to their investments in Actinium.

Background of the Case

On August 5, 2024, Actinium Pharmaceuticals issued a press release concerning a regulatory update related to its planned Biologics License Application (BLA) for Iomab-B, a treatment aimed at patients suffering from active relapsed or refractory acute myeloid leukemia (r/r AML). The critical announcement disclosed that the U.S. Food and Drug Administration (FDA) had determined that the Phase 3 SIERRA trial did not provide sufficient data to support a BLA filing for Iomab-B, despite achieving significant primary endpoints.

This disappointing regulatory news led to a dramatic decline in Actinium’s stock price, which plummeted by $3.69, equivalent to nearly 60%, closing at $2.48 per share on the same day. Such price falls are alarming signals for investors and raise concerns regarding potential violations of securities laws by the company.

Investor Participation

Investors are encouraged to take immediate action. If you purchased or otherwise acquired securities of Actinium during the specified Class Period, you have until May 26, 2025, to ask the Court to appoint you as Lead Plaintiff in this lawsuit. Individuals interested in joining this class action can request a copy of the complaint and receive further information by contacting Pomerantz LLP directly. The law firm's contact person for this case is Danielle Peyton, who can be reached via email at [email protected] or by telephone at 646-581-9980, extension 7980.

Suggested Information for Inquiry

When reaching out, investors should include essential information such as:

• - Full Name
• - Mailing Address
• - Telephone Number
• - The number of shares purchased

This information will assist in the legal process and ensure proper communication with investors about the ongoing case.

About Pomerantz LLP

Pomerantz LLP is a prominent law firm known for its expertise in corporate, securities, and antitrust class litigation. Established over 85 years ago by Abraham L. Pomerantz, often recognized as a pioneer in securities class actions, the firm has a rich history of advocating for victims of securities fraud and corporate misconduct. Pomerantz aims to recover significant damages on behalf of class members, having achieved numerous multimillion-dollar settlements in the past.

For further details, interested parties can visit Pomerantz’s official website for valuable resources and updates on this ongoing litigation.

Conclusion

The filing of a class action lawsuit against Actinium Pharmaceuticals is a crucial development for investors affected by the recent downturn in the company’s stock, driven by unfavorable regulatory news. With impending deadlines for involvement in the lawsuit, it's recommended that investors remain proactive and engaged in the proceedings to protect their financial interests.